ELISA/assay

Canine Complement 1q ELISA Kit

MBS735751

48-Strip-Wells

470 USD

ELISA Kit

Canine Complement 1q ELISA Kit

Complement 1q

complement C1q tumor necrosis factor-related protein 5; Complement C1q tumor necrosis factor-related protein 5; complement C1q tumor necrosis factor-related protein 5; myonectin; C1q TNF-alpha-related protein 5; C1q and tumor necrosis factor related protein 5

C1q

C1QTNF5; C1QTNF5; CTRP5; CTRP5; UNQ303/PRO344

C1QT5_HUMAN

Canine

This assay has high sensitivity and excellent specificity for detection of C1Q. No significant cross-reactivity or interference between C1Q and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between C1Q and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 1.0 ng/mL.

Intended Uses: This C1Q ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Canine C1Q. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Immunology

Principle of the assay: C1Q ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-C1Q antibody and an C1Q-HRP conjugate. The assay sample and buffer are incubated together with C1Q-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the C1Q concentration since C1Q from samples and C1Q-HRP conjugate compete for the anti-C1Q antibody binding site. Since the number of sites is limited, as more sites are occupied by C1Q from the sample, fewer sites are left to bind C1Q-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The C1Q concentration in each sample is interpolated from this standard curve.

14149712

NP_056460.1

NM_015645.4

25,298 Da

This gene encodes a member of a family of proteins that function as components of basement membranes and may play a role in cell adhesion. Mutations in this gene have been associated with late-onset retinal degeneration. The protein may be encoded by either a bicistronic transcript including sequence from the upstream membrane frizzled-related protein gene (MFRP), or by a monocistronic transcript expressed from an internal promoter. [provided by RefSeq, Jun 2013]

C1QTNF5: Defects in C1QTNF5 are a cause of late-onset retinal degeneration (LORD). LORD is an autosomal dominant disorder characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits in the retinal fundus, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy. Protein type: Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 11q23.3. Cellular Component: collagen. Disease: Late-onset Retinal Degeneration

48-Strip-Wells

470 USD

96-Strip-Wells

675